Zhejiang Garden Pharmaceutical Co., Ltd.

The test preparation was ezetimibe atorvastatin calcium tablets (specification: 10 mg/10 mg) owned by Zhejiang Huayuan Pharmaceutical Co., Ltd., and the reference preparation was ezetimibe atorvastatin calcium tablets (ATOZET®, specification: 10 mg/10 mg) marketed by Merck Sharp & Dohme. The pharmacokinetic parameters and relative bioavailability of the two preparations after single administration in the fasting and postprandial states were investigated to evaluate whether the two preparations were bioequivalent. At the same time, the safety and tolerability of the two preparations in healthy humans were evaluated.

Main purpose: To compare the absorption rate and extent of the doxofylline tablets (trade name: ANSIMAR®, reference preparation) in healthy human bodies with the doxofylline tablets (trade name: ANSIMAR®, reference preparation) certified by ABC Farmaceutici S.p.A., and investigate the bioequivalence of the two preparations in humans. Secondary purpose: To observe the safety of the doxofylline tablets (test preparation) and the reference preparation (ANSIMAR®) in healthy subjects.

This study aimed to investigate the pharmacokinetic characteristics of single fasting and postprandial oral administration of carbidopa 50 mg, levodopa 200 mg sustained-release tablets produced by Zhejiang Thermo Pharmaceutical Co., Ltd.; carbidopa 50 mg, levodopa 200 mg sustained-release tablets (Xining®) produced by MSD Pharma (Singapore) Pte. Ltd. and Savio Industrial S.r.L. were used as reference preparations. The pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations were compared, the bioequivalence of the two preparations in humans was evaluated, and the safety of the two preparations in healthy subjects was observed.